Gelonghui, January 22丨Mengke Pharmaceutical (688373.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve operating income of about 890 million yuan to 90.2 million yuan in 2023. Compared with the same period last year, it will increase 40.7933 million yuan to 43.7933 million yuan, an increase of 84.62% to 90.84% over last year.
The net profit attributable to shareholders of listed companies in 2023 is estimated to be approximately 430,000 yuan to -360.01 million yuan, an increase of 139.7013 million yuan to 209.7013 million yuan over the same period last year, and a year-on-year increase of 63.41% to 95.19%. Net profit attributable to shareholders of listed companies in 2023 after deducting non-recurring profit and loss is estimated to be about -460.000 million yuan to -390.00 million yuan, an increase of 122.3519 million yuan to 192.3519 million yuan over the same period last year, and a year-on-year increase of 45.71% to 71.87%.
During the reporting period, the company actively expanded its academic promotion efforts and further expanded the distribution network of pharmaceutical commercial companies. At the same time, the number of hospitals covered increased, so its main business revenue grew rapidly. Although the company's revenue increased during the reporting period, R&D expenditure continued to increase as the clinical progress of the company's ongoing research projects continued to advance and the size of the R&D personnel team expanded. At the same time, with the active development of the company's sales business, sales expenses also increased during the reporting period. Overall, the company's net profit continued to lose during the reporting period.